This MedLibrary.org supplementary page on Aminocaproic acid is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Aminocaproic acid
|
|
| Systematic (IUPAC) name | |
| 6-aminohexanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | B02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C6H13NO2 |
| Mol. mass | 131.173 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Renal |
| Half life | 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Aminocaproic acid (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the amino acid lysine, which makes it an effective inhibitor for enzymes which bind that particular residue. Such enzymes include proteolytic enzymes (which break down proteins) including plasminogen, the enzyme responsible for fibrinolysis. For this reason it is effective in treatment of some bleeding disorders and is marketed as Amicar.
Contents |
Mechanism of action
Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine analogue, it binds reversibly to the kringle domain of the enzyme plasminogen and blocks binding of fibrin, which is normally activated to plasmin.
Clinical use
Aminocaproic acid is used to treat excessive postoperative bleeding. It can be given orally or intravenously. One scenario where it may be useful is to treat bleeding after dental extractions in patients with hemophilia, because the oral mucosa is rich in plasminogen activators. A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting.citation needed
Side effects
Its side effects are mainly related to the gastrointestinal tract and include nausea, vomiting, abdominal pain, and diarrhea. It may cause generalised myalgia. The main risk associated with aminocaproic acid is the increased risk for thrombosis because of the inhibition of fibrinolysis.
Other uses
Aminocaproic acid is occasionally used in BN-PAGE buffers, not for its effects as a proteolysis inhibitor, but to solubilize membrane proteins in place of sodium chloride (which is incompatible with PAGE in the necessary concentration). Percent recovery of protein complexes increases linearly with the concentration of inhibitor (between 125 mM and 750 mM)[1].
References
 |
This article does not cite any references or sources. (November 2007) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
- ^ Schägger, H and Von Jagow, G (1991). Blue Native Electrophoresis for Isolation of Membrane Protein Complexes in Enzymatically Active Form. Analytical Biochemistry 199 (2): 223-231.
|
||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 14 May 2008, at 17:50.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Aminocaproic acid".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.